We also found that MsA treatment (10–50 μM) significantly reduces tau phosphorylation at Ser404, mechanistically linking PI3K/AKT/GSK3β activation to tauopathy mitigation (Figure 7). The gene discussed is MAPT; the disease is tauopathy.